ASP Isotopes Inc. Common Stock (ASPI)
🔔 Watch stock
symbol.quality_heading
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
Whoever buys today is betting that at least two of the five stories deliver before dilution and the cost base eat through the war chest — while carrying key contracts the customer can cancel at will, a certified control weakness and a group in permanent rebuild. Whoever waits checks three pieces of evidence in every new quarterly report (10-Q): the first invoiced C-14/Si-28 shipments, the closing and terms of the NOBA spin-out, and the trajectory of the share count. As long as that evidence is missing, the stock is a bundle of hopes at about 30 times continuing revenue. The decision is yours.
symbol.quality_note
ASP Isotopes offers several megatrends at once: nuclear medicine, silicon-28 for quantum computers, HALEU nuclear fuel for TerraPower, plus helium from South Africa. On Reddit the stock just jumped from rank 785 to 233 of the most-discussed tickers — on a modest 2 mentions in 24 hours (ApeWisdom, as of July 17, 2026). We read the annual reports (10-K) for 2024 and 2025, the quarterly report (10-Q) as of March 31, 2026, and the June 2026 merger filings: zero revenue from enriched isotopes, 76 percent of 2025 revenue from a Hong Kong road-construction side business, a $159.8 million net loss, a share count that has more than doubled since the end of 2023 — and a genuinely full war chest. Not investment advice — just an inventory of which of the five stories actually earns money yet.
Read the analysis
Stock Watch
This analysis is as of July 17, 2026. Stock Watch will tell you what's changed at ASPI since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 4.00 $ — 5% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralGeprüft am 17.07.2026 gegen den Geschäftsbericht (10-K) für 2025 (eingereicht 10.04.2026), den 10-K für 2024 (31.03.2025) und die vier jüngsten Quartalsberichte (10-Q, zuletzt zum 31.03.2026): In den ausgewerteten SEC-Filings von ASP Isotopes findet sich kein wesentlicher KI-Bezug. Die einzige Erwähnung von „artificial intelligence“ steht im Si-28-Kapitel des 10-K 2025 als Zukunftsprognose über Quantencomputer („Quantum computers are expected to be thousands or millions of times more powerful …, opening new frontiers and opportunities in many industries, including medicine, artificial intelligence, cybersecurity, global logistics and global financial systems.“) — KI ist dort ein möglicher Endmarkt der Quantencomputer, für die ASP Isotopes angereichertes Si-28 liefern will, nicht mehr. Weder KI-Umsatzquelle noch operativer KI-Einsatz noch konkretes KI-Geschäftsrisiko fürs eigene Modell; die vier 10-Q und der 10-K 2024 enthalten überhaupt keine KI-Treffer. Endmarkt-Nähe (Halbleiter/Quantencomputing) allein begründet nach dem Kriterienkatalog kein „verkauft“ — es bleibt bei „neutral“.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-05-20 · 10-Q 2025-11-19 · 10-Q 2025-08-14 · 10-Q 2025-05-20 · 10-K 2026-04-10 · 10-K 2025-03-31
Rated on July 17, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 225.0% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 1
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.44 | -2.40 – -0.47 | 31 | -72.9% | 2 |
| 12/31/2027 | -1.16 | -2.70 – -0.32 | 88 | 19.4% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.39 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.16 | – | 1 | 175.80 | -768.90 | -4 | -7 |
| 2025: Q1 | -0.12 | – | 1 | 31.20 | -766.40 | -3 | -6 |
| 2025: Q2 | -1.03 | – | 1 | 17.20 | -6,265.70 | -8 | -10 |
| 2025: Q3 | -0.15 | – | 5 | 349.40 | -263.30 | -9 | -12 |
| 2025: Q4 | -0.70 | – | 17 | 1,295.30 | -472.40 | -18 | -20 |
| 2026: Q1 | -0.06 | – | 4 | 279.30 | -164.50 | -18 | -24 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 23 | -10 | -10 | -0.30 | – | – | – |
| 2021 | – | -3 | -3 | -0.08 | -1 | 6 | 7 |
| 2022 | 0 | -5 | -5 | -0.14 | -3 | 10 | 13 |
| 2023 | 0 | -16 | -16 | -0.49 | -5 | 16 | 30 |
| 2024 | 4 | -26 | -32 | -0.58 | -17 | 48 | 94 |
| 2025 | 24 | -57 | -175 | -2.11 | -38 | 204 | 513 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
$207.3 million in cash plus $83.2 million in short-term investments (March 31, 2026) after $371.6 million of financing inflows in 2025 — including a stock offering that raised $199.3 million net at $12.25 per share (October 2025). Per the 10-K, the war chest funds the buildout for well over twelve months.
Both Pretoria plants have been in commercial production since the first half of 2025, and three Si-28 purchase agreements plus a C-14 contract with a take-or-pay clause are signed — but there is no enriched-isotope revenue yet; the scheduled first shipments (C-14 mid-2026, Si-28 Q2 2026) are the real litmus test.
76 percent of 2025 revenue came from Hong Kong construction acquisition Skyline (bought August 2025, deconsolidated March 29, 2026); Renergen was acquired in January 2026 and slated for spin-out as NOBA in June 2026. A group that rotates faster than its filings makes comparability nearly impossible (10-K 2025; 10-Q as of 03/31/2026; 8-K of 06/25/2026).
Net loss of $159.8 million in 2025 (including $123.7 million of fair-value losses on its own convertible notes; operating cash outflow $37.8 million); share count up from 48.9 million to 125.9 million in 27 months (+157 percent), with another $199.3 million of QLE convertible notes awaiting conversion into equity.
A material weakness in internal controls (10-K 2025, Item 9A), 10-K and 10-Q filed only after deadline extensions, a securities class action following a short-seller report (S.D.N.Y., since 12/04/2024), the CEO's $2.5 million private investment in acquisition target Skyline, and 19 insider sales without a single purchase (data as of July 10, 2026).
Roughly $825 million of market value (data as of July 10, 2026) for a good $535 million of operating package net of cash — at about 30 times continuing revenue. The TerraPower agreements (terminable at any time), the QLE listing and the NOBA spin-out could make value visible; none of it is proven today.
ASP Isotopes is a betting slip with five fields and a genuine war chest: roughly $290 million of liquidity, producing plants in Pretoria and TerraPower as a well-funded contract partner stand against zero revenue from the core business, 76 percent of 2025 revenue from an already-divested road builder, a $159.8 million loss, a share count that has more than doubled since the end of 2023, a certified control weakness and a pending class action. The scheduled first shipments of C-14 and Si-28 from mid-2026 are the first real day of proof. Not investment advice.
- ASPI reached the research list via the Reddit hype scanner: just 2 mentions in 24 hours, but a jump from rank 785 to rank 233 of the most-discussed stocks (ApeWisdom, as of July 17, 2026) — attention building, no noise yet. In our in-house stock scanner, the stock appears in no ranking filter (data as of July 10, 2026).
- Scanner metrics (P/S, Piotroski, Altman Z, fundamental grade) are computed on trailing twelve-month figures; the Skyline revenue (consolidated August 2025 through March 2026) is partly baked in, while the announced first shipments and the NOBA spin-out naturally are not.
- Price and valuation figures are dated July 10, 2026 (around $6.40 per share, roughly $825 million market value); analyses are evergreen, daily prices are not a buy argument. The Noble Africa/ENDRA merger (agreement of June 25, 2026) was still subject to approvals and closing conditions as of this writing.
About the Company
ASP Isotopes Inc., ein Unternehmen für fortschrittliche Materialien in der Entwicklungsphase, beschäftigt sich mit der Produktion, dem Vertrieb, der Vermarktung und dem Verkauf von Isotopen in Südafrika, Hongkong und den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 271 |
| Headquarters | Dallas, TX |
| Address | 2200 Ross Avenue, 75201 Dallas, United States |
| Phone | 214 432 8219 |
| Website | aspisotopes.com |
| IPO Date | 10. Nov 2022 |
| ISIN | US00218A1051 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Paul Elliot Mann C.F.A. | Executive Chairman & CEO | 1977 |
| Heather Kiessling | Chief Financial Officer | 1965 |
| Robert Ainscow | Chief Operating Officer | 1977 |
| Nicholas Michael Mitchell | Co-Chief Operating Officer | 1980 |
| Hendrik Strydom B. Sc, M. Sc, Ph.D. | Chief Technology Officer | 1961 |
| Donald George Ainscow | EVP, General Counsel & Secretary | 1981 |
| Hendrik T. van Wyk | Head of Engineering | – |
| Xandra van Heerden Ph.D. | Head of Research & Development | – |
| Stefano Marani | President of Electronics & Space | 1978 |
| Gerdus Kemp M.D., Ph.D. | Medical Director & CEO of Pet Labs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.